FR3102064B1 - Food supplement used to help fight atherosclerosis and prevent cardiovascular diseases - Google Patents
Food supplement used to help fight atherosclerosis and prevent cardiovascular diseases Download PDFInfo
- Publication number
- FR3102064B1 FR3102064B1 FR1911726A FR1911726A FR3102064B1 FR 3102064 B1 FR3102064 B1 FR 3102064B1 FR 1911726 A FR1911726 A FR 1911726A FR 1911726 A FR1911726 A FR 1911726A FR 3102064 B1 FR3102064 B1 FR 3102064B1
- Authority
- FR
- France
- Prior art keywords
- ingredient consisting
- cardiovascular diseases
- atherosclerosis
- food supplement
- prevent cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 235000015872 dietary supplement Nutrition 0.000 title abstract 2
- 239000004615 ingredient Substances 0.000 abstract 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 235000016108 Argania sideroxylon Nutrition 0.000 abstract 1
- 241001673902 Argania spinosa Species 0.000 abstract 1
- 102100022043 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Human genes 0.000 abstract 1
- 101710154595 Coenzyme Q-binding protein COQ10 homolog A, mitochondrial Proteins 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 239000010478 argan oil Substances 0.000 abstract 1
- 239000007765 cera alba Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 229960001109 policosanol Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 229960000984 tocofersolan Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- 239000002076 α-tocopherol Substances 0.000 abstract 1
- 235000004835 α-tocopherol Nutrition 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Complément alimentaire pour son utilisation dans la lutte contre l’athérosclérose et la prévention des maladies cardiovasculaires, le complément étant sous forme adapté à un usage par voie orale, et permettant de réduire l’oxydation du LDL cholestérol, et l’amélioration du profil lipidique par baisse du taux plasmatique du cholestérol total et de sa fraction LDL, caractérisé en ce qu’il comprend en combinaison : -un premier ingrédient constitué d’huile d’argan vierge(Argania Spinosa) -un deuxième ingrédient constitué de Policosanol -un troisième ingrédient constitué de Coenzyme Q10 -un quatrième ingrédient constitué de vitamine E naturel D-alpha-tocophérol -un cinquième ingrédient constitué de cire d’abeille blanche.Food supplement for its use in the fight against atherosclerosis and the prevention of cardiovascular diseases, the supplement being in a form suitable for oral use, and making it possible to reduce the oxidation of LDL cholesterol, and improve the lipid profile by reduction in the plasma level of total cholesterol and its LDL fraction, characterized in that it comprises in combination: - a first ingredient consisting of virgin argan oil (Argania Spinosa) - a second ingredient consisting of Policosanol - a third ingredient consisting of Coenzyme Q10 - a fourth ingredient consisting of natural vitamin E D-alpha-tocopherol - a fifth ingredient consisting of white beeswax.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1911726A FR3102064B1 (en) | 2019-10-19 | 2019-10-19 | Food supplement used to help fight atherosclerosis and prevent cardiovascular diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1911726A FR3102064B1 (en) | 2019-10-19 | 2019-10-19 | Food supplement used to help fight atherosclerosis and prevent cardiovascular diseases |
| FR1911726 | 2019-10-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3102064A1 FR3102064A1 (en) | 2021-04-23 |
| FR3102064B1 true FR3102064B1 (en) | 2024-01-19 |
Family
ID=69810963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1911726A Active FR3102064B1 (en) | 2019-10-19 | 2019-10-19 | Food supplement used to help fight atherosclerosis and prevent cardiovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR3102064B1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2351141B1 (en) * | 2009-06-26 | 2011-11-24 | Olifarma, S.L. | FUNCTIONAL OILS BASED ON OLIVE OIL. |
| IT201600078969A1 (en) * | 2016-07-27 | 2018-01-27 | Buonamici Gugliemo | DIETARY SUPPLEMENT |
-
2019
- 2019-10-19 FR FR1911726A patent/FR3102064B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| FR3102064A1 (en) | 2021-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Suppression of acute ethanol-induced hepatic steatosis by docosahexaenoic acid is associated with downregulation of stearoyl-CoA desaturase 1 and inflammatory cytokines | |
| Brenner | Remission of renal disease: recounting the challenge, acquiring the goal | |
| HK1258159A1 (en) | Prolyl hydroxylase inhibitors and methods of use | |
| Harris et al. | Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer | |
| WO2008087348A3 (en) | Emulsion comprising at least one retinoid and benzoyl peroxide | |
| PH12015501523A1 (en) | Formulations of 4-amino-2-(2, 6-dioxopiperidine-3-yl) isiondoline-1, 3-dione | |
| Merendino et al. | Docosahexaenoic acid induces apoptosis in the human PaCa-44 pancreatic cancer cell line by active reduced glutathione extrusion and lipid peroxidation | |
| WO2008087354A3 (en) | Cream-gel comprising at least one retinoid and benzoyl peroxide | |
| MX2009003920A (en) | Statin and omega-3 fatty acids for reduction of apo-b levels. | |
| NZ734905A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| MA28102A1 (en) | PHARMACEUTICAL FORMULATIONS, METHODS AND ADMINISTRATION DIAGRAMS FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES | |
| EE200300599A (en) | Coenzyme Q and EPA or other essential fatty acids | |
| EA201100756A1 (en) | METHOD OF TREATMENT OR PREVENTION OF THROMBOSIS BY USING DAGIGATRAN ETHESYLATE OR ITS SALT WITH AN IMPROVED SAFETY PROFILE AS COMPARED TO STANDARD TREATMENT WARFARIN | |
| RU2012114832A (en) | NUTRITIONAL COMPOSITIONS FOR MODULATION OF INFLAMMATION CONTAINING EXOGENOUS VITAMIN K2 | |
| PE20090345A1 (en) | BAKED COMPOSITION | |
| MX2015014656A (en) | Sustained-release formulations of colchicine and methods of using same. | |
| ATE516016T1 (en) | SELF-EMULSIFYING FORMULATIONS OF CETP INHIBITORS | |
| MA45754A1 (en) | Pharmaceutical use of a composition based on sustained release pirfenidone (pfd-lp) for the reversal of human fatty liver disease (nafld / nash) | |
| Lubet et al. | Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy | |
| EP3981399A4 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| EA201100755A1 (en) | METHOD OF TREATMENT OR PREVENTION OF THROMBOSIS BY USING DABIGATRANE ETHSYLATE OR ITS SALT WITH IMPROVED EFFICIENCY IN COMPARISON WITH STANDARD TREATMENT WARFARIN | |
| FR3102064B1 (en) | Food supplement used to help fight atherosclerosis and prevent cardiovascular diseases | |
| US10682334B2 (en) | Treatment for non-alcoholic fatty liver diseases | |
| MX2021002902A (en) | Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient. | |
| US20150119414A1 (en) | Statin and omega 3 fatty acids for reduction of apolipoprotein-b levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| EXTE | Extension to a french territory |
Extension state: PF |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20210423 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |